The October 20, 2017, article by Demetri et al entitled “Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine” (J Clin Oncol 10.1200/JCO.2016.71.6605) was published with an error.
The second sentence of the third paragraph under the section heading Efficacy reads: “PFS was longer with eribulin treatment compared with dacarbazine in patients with dedifferentiated, myxoid/round cell, or pleomorphic LPS subtypes (HR, 0.69; 95% CI, 0.36 to 1.33; HR, 0.57; 95% CI, 0.29 to 1.11; and HR, 0.34; 95% CI, 0.09 to 1.30; respectively; Fig 2B).”
This should read: “The HRs for PFS favored eribulin treatment compared with dacarbazine in patients with dedifferentiated, myxoid/round cell, or pleomorphic LPS subtypes (HR, 0.69; 95% CI, 0.36 to 1.33; HR, 0.57; 95% CI, 0.29 to 1.11; and HR, 0.34; 95% CI, 0.09 to 1.30; respectively; Fig 2B).”
This has been corrected as of December 20, 2017. The authors apologize for the error.